3 research outputs found
Effect of calcium on anxiolytic activity of diazepam and verapamil in rats
Objective: To analyze the role of calcium in anxiety and its effect on
anxiolytic activity of diazepam and verapamil. Materials and Methods:
Study was conducted using female albino rats in light and dark arena; a
nonconflicting animal experimental model for anxiety. Animals were
divided into six groups with six animals in each group. Test drugs,
calcium gluconate (10 mg/kg), diazepam (1 mg/kg), verapamil (5 mg/kg),
calcium + diazepam, and calcium + verapamil were administered
intraperitoneally. Percentage of time spent in light arena and number
of entries into light arena were the two parameters observed for 5 min
after 30 min of drug administration. ANOVA test was used for
statistical analysis. Results: Compared to the control group, diazepam
group, and calcium group, only calcium + diazepam group showed
considerable increase in mean percentage of time spent in light arena.
However, this increase was statistically insignificant. In the case of
total number of entries into light arena, animals in calcium + diazepam
group showed statistically significant increase in total number of
entries into light arena when compared to calcium group and diazepam
group. Conclusion: Results of the study suggest that calcium may
enhance the anxiolytic activity of diazepam, but has no effect on
anxiolytic activity of verapamil
Patterns of epidermal growth factor receptor testing across 111 tertiary care centers in India: Result of a questionnaire-based survey
Background: We conducted a survey of 111 medical oncologists across India to understand the current pattern of epidermal growth factor receptor (EGFR) mutation testing at their respective centers. Methods: Medical oncologists from 111 institutes across India were interviewed face to face using a structured questionnaire. They were divided into two groups – Group 1 with in-house EGFR testing and Group 2 who send samples to central/commercial laboratories outside their institutions. Answers of the two groups were analyzed to see the prevailing patterns of EGFR testing and differences between the two groups if any. Results: Ninety-five percent (105/111) of medical oncologists recommended testing for EGFR mutations in patients with adenocarcinoma histology and 40% (44/111) recommended EGFR testing in squamous cell histology. The average time duration to get EGFR test results was 10 days in Group 1 centers versus 18 days in Group 2 centers. Ninety-six percent (106/111) of the medical oncologists from Group 1 centers requested for factoring additional sample for biomarker testing compared to 69% (77/111) of the oncologists from Group 2 centers. Sixty-nine percent (77/111) of medical oncologists in Group 1 centers would prefer to wait for the test results before initiating treatment compared to 46% (51/111) in Group 2. EGFR tyrosine-kinase inhibitors were used in only approximately 60% of patients with diagnosed EGFR mutation in the first line. For patients in whom chemotherapy was initiated while waiting for test results, 50% (56/111) of medical oncologists would prefer to complete 4–6 cycles before switching to targeted therapy. At the time of progression, rebiopsy was possible in approximately 25% of the patients. Conclusions: Turnaround time for molecular testing should improve so that eligible patients can benefit from targeted therapies in the first line. There is a need to increase the awareness among pulmonologists, oncologists, and interventional radiologists regarding the importance of adequate samples required for molecular tests